| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
MB-Buf (5 μM, 660 nm laser irradiation for 0-5 min) induces the production of singlet oxygen, superoxide anion and hydroxyl radicals [1]. MB-Buf (0.1-1 μM, 6 h pretreatment with 660 nm laser irradiation for 5 min) showed the strongest inhibitory activity against MCF-7, MDA-MB-231 and 4T1 cells, with IC50 values of 28.74, 36.82 and 64.41 nM, respectively [1]. MB-Buf (0.1-1 μM, 6 h pretreatment with 660 nm laser irradiation for 5 min) induces the production of reactive oxygen species and ferroptosis in MCF-7 cells [1]. MB-Buf (10-100 nM, 6 h pretreatment + 660 nm laser irradiation for 2-5 min) degrades GPX4 in MCF-7 cells [1]. MB-Buf (0.5 μM, 6 h pretreatment with 660 nm laser irradiation for 5 min) inhibits the migration of MCF-7 cells[1]. MB-Buf (0.5 μM, 6 h pretreatment with 660 nm laser irradiation for 5 min) induces apoptosis in MCF-7 cells[1].
|
|---|---|
| ln Vivo |
MB-Buf (1 mg/kg, intravenous injection, once every 3 days) combined with USB can adsorb tumor growth in 4 T1-Luci xenograft mice[1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MCF-7 cells Tested Concentrations: 10, 50 and 100 nM Incubation Duration: 6 h pretreatment + 660 nm laser irradiation for 2-5 min Experimental Results: Reduced GPX4 levels. Immunofluorescence[1] Cell Types: MCF-7 cells Tested Concentrations: 0.1, 0.5 and 1 μM Incubation Duration: 6 h pretreatment with 660 nm laser irradiation for 5 min Experimental Results: Increased ROS production. |
| Animal Protocol |
Animal/Disease Models: 4 T1-Luci xenograft mice models[1]
Doses: 1 mg/kg Route of Administration: Intravenously injection, every 3 days, 660 nm laser irradiation for 5 min at 6 h post-injection Experimental Results: Reduced tumor volume. Had no significant changes in mouse body weight and no obvious toxicity in major organs. |
| References |
| Molecular Formula |
C47H55N3O5S
|
|---|---|
| Molecular Weight |
774.02
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2920 mL | 6.4598 mL | 12.9196 mL | |
| 5 mM | 0.2584 mL | 1.2920 mL | 2.5839 mL | |
| 10 mM | 0.1292 mL | 0.6460 mL | 1.2920 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
